ArticleJournal of experimental & clinical cancer research : CR2009
Does vimentin help to delineate the so-called 'basal type breast cancer'?
Article in Journal of experimental & clinical cancer research : CR, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Prognostic Value of Vimentin in Triple Negative Breast Cancer Patients Depends on Chemotherapy Regimen and p53 Mutant Expression.Breast cancer (Dove Medical Press) · 2023Article
- Identification of the lymph node metastasis-related automated breast volume scanning features for predicting axillary lymph node tumor burden of invasive breast cancerFrontiers in endocrinology · 2022Article
- Knocking down USP39 Inhibits the Growth and Metastasis of Non-Small-Cell Lung Cancer Cells through Activating the p53 Pathway.International journal of molecular sciences · 2020Article
- Is vimentin a potential prognostic factor for patients with triple-negative breast cancer?Journal of cancer research and clinical oncology · 2020Article
- Up-regulation of FAT4 enhances the chemosensitivity of colorectal cancer cells treated by 5-FU.Translational cancer research · 2020Article
- The UbL-UBA Ubiquilin4 protein functions as a tumor suppressor in gastric cancer by p53-dependent and p53-independent regulation of p21.Cell death and differentiation · 2019Article
- Epithelial-Mesenchymal Transition Markers in Breast Cancer and Pathological Responseafter Neoadjuvant Chemotherapy.Breast cancer : basic and clinical research · 2018Article
- Clinicopathological Significance of Vimentin and Cytokeratin Protein in the Genesis of Squamous Cell Carcinoma of Cervix.Obstetrics and gynecology international · 2016Article
- FAT4 functions as a tumour suppressor in gastric cancer by modulating Wnt/β-catenin signalling.British journal of cancer · 2015Article
- In stage II/III lymph node-positive breast cancer patients less than 55 years of age, keratin 8 expression in lymph node metastases but not in the primary tumour is an indicator of better survival.Virchows Archiv : an international journal of pathology · 2015Article
- Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer.BMC veterinary research · 2014Article
- Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype.International journal of clinical and experimental pathology · 2014Article
- Novel role of MDA-9/syntenin in regulating urothelial cell proliferation by modulating EGFR signaling.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Vimentin as a poor prognostic factor for triple-negative breast cancer.Journal of cancer research and clinical oncology · 2013Article
- Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?The EPMA journal · 2013Article
- Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition.PloS one · 2013Article
- Are breast cancer molecular classes predictive of survival in patients with long follow-up?Disease markers · 2013Article
- Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma.Translational oncology · 2011Article
- Biomarkers for Basal-like Breast Cancer.Cancers · 2010Article
- Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1).Journal of experimental & clinical cancer research : CR · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVimentin is one of the cytoplasmic intermediate filament proteins which are the major component of the cytoskeleton. In our study we checked the usefulness of vimentin expression in identifying cases of breast cancer with poorer prognosis, by adding vimentin to the immunopanel consisting of basal type cytokeratins, estrogen, progesterone, and HER2 receptors.
methods179 tissue specimens of invasive operable ductal breast cancer were assessed by the use of immunohistochemistry. The median follow-up period for censored cases was 90 months.
results38 cases (21.2%) were identified as being vimentin-positive. Vimentin-positive tumours affected younger women (p = 0.024), usually lacked estrogen and progesterone receptor (p < 0.001), more often expressed basal cytokeratins (<0.001), and were high-grade cancers (p < 0.001). Survival analysis showed that vimentin did not help to delineate basal type phenotype in a triple negative (ER, PgR, HER2-negative) group. For patients with 'vimentin or CK5/6, 14, 17-positive' tumours, 5-year estimated survival rate was 78.6%, whereas for patients with 'vimentin, or CK5/6, 14, 17-negative' tumours it was 58.3% (log-rank p = 0.227).
conclusionWe were not able to better delineate an immunohistochemical definition of basal type of breast cancer by adding vimentin to the immunopanel consisted of ER, PgR, HER2, CK5/6, 14 and 17 markers, when overall survival was a primary end-point.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.